TRAINING & EDUCATION
working on the trial and the rigorous procedures that new treatments go through before they are allowed to progress to trials in NHS patients.”
“I’d recommend taking part in a clinical trial to any patient if they have the opportunity. I am living proof that for best patient care and outlook, treatment at an expert specialist, research active centre is crucial.” The opportunity to access new drugs, medical devices or diagnostics via a commercial trial doesn’t only have benefits to patients but also to NHS trusts and clinicians who have the opportunity to offer their patients the latest treatments. Professor Danson stated: “We believe that patients should be offered a clinical trial as part of their standard care in the NHS and, as I see patients in a research centre, it would be unusual for us not to offer trials to patients if that was a possible option for their condition. “Patients are very receptive to the idea of clinical trials and due to the nature of a randomised controlled trial, they are aware they may not be in the group of patients that receives the new drug but this does not put them off being open to the idea of a trial. Many patients participate, not only as a treatment option for themselves, but because feel they are contributing towards treatment options of the future - it’s commonly said by patients that this treatment might not help me but if it helps future generations receive better care, I will feel like I’m doing some good.”
In partnership with the NHS, the NIHR supported more than 1300 commercial research studies, which is an 11% rise on the previous year, and to achieve the 45% rise in patient recruitment
is an outstanding achievement. Matt Cooper, NIHR Clinical Research Network
That very powerful message is what motivates many doctors and nurses into supporting research studies and trials in the NHS. Offering clinical trials and studies to patients has benefits for the NHS trust also, and in the case of commercial research, the drugs or devices being tested as part of a clinical trial are supplied by the company sponsoring the trial and represent a saving to the resources and prescribing budgets in the NHS. In a report1 published by the NIHR CRN, NHS trusts in England were estimated to receive £6658 in revenue from life sciences companies for each patient recruited into commercial clinical research studies. At a time when NHS resources are stretched clinical research can make a valuable contribution to NHS trusts and the wider health economy.
The Government also sees life sciences research as a pivotal area for growth, as demonstrated in the NIHR CRN report2
which showed that the national NIHR CRN Portfolio of research was worth £2.4 billion to the UK economy.
In response to the Life Sciences Industrial Strategy3 - a report to the Government from the life sciences sector, the Government launched its Industrial Strategy white paper4 in November 2017. The life sciences industry plays a major part in the white paper, which highlights the great importance of a strong life sciences industry to the future of the UK’s economic success. A report published by PwC on The economic contribution of the UK Life Science Industry5 in March last year, determined the value added to the UK economy by the life sciences sector. As a major contributor to the UK economy and developer of life-saving and life-enhancing medicines to patients, the industry supports over 62,000 employees and it has the highest productivity rate of any high technology sector with exports worth £30 bn. Matt Cooper, NIHR director of business
Broncoflex® Disposable Bronc B
• Exporxports images anports images nmages an ailabl
integrgrate SCed SC E Exp
mag ila ilable ilable n 2 s able in 2 s
• Eradicates repair or disinfection cos images and video via a US
A single use sterile v o s of cross conrisk epa
s g a c
v novat • Innov
novative visualisation system with ed SCREENi® t
epair or disinfection cnfection co v ualisation syst
i nfection co n syste
• Available in 2 scope sizes•Available in 2 scope sizes• Availab
ges and video 2
nd video v a U pe sizes
SCREENi touch scrch sc e ag
ages an v eo e s
system witt m with h screen
o via a US
c on cos wt
nd video via a US pe sizes
c • A single us x s
v d a
a B
• A single use sterile video bronchoscr • No risk of cross contamination • Eradicates repair • Innov
use sterile video bronchoscr nch c
nch inationt n
c
choscope Now Av ilable From CMS c w va m M
For mor For Fo cont NOVEMBER 2018 Ce o entral M
For morre information contact Centraonttact Central Medica ppS p
ore information o
n or
cal Supplies on o
n onthe Bron on info
n on th Bhe Bron no
he Br ncoflex and S o@cent
ntralmedtral
x® and SCRE edical.c
dS RE
EEN
EENi
EENi®
al.c.co k or 01538 399 541
co.uk o 015 9 541 1
WWW.CLINICALSERVICESJOURNAL.COM I 23
t
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88
